debrisoquin and cimetidine

debrisoquin has been researched along with cimetidine in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (50.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	2 (20.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Desager, JP; Harvengt, C; Horsmans, Y; Leclercq, V; Van Nieuwenhuyze, Y	1
James, CA; Philip, PA; Rogers, HJ	1
Crewe, HK; Lennard, MS; Tucker, GT; Woods, HF	1
Kairaluoma, M; Pasanen, M; Pelkonen, O; Sotaniemi, EA; Taskinen, T	1
Spina, E; Steiner, E	1
Brøsen, K; Gram, LF	1

Trials

1 trial(s) available for debrisoquin and cimetidine

Article	Year
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. British journal of clinical pharmacology, 1993, Volume: 35, Issue:6 Topics: Adult; Aged; Benzamides; Cimetidine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Moclobemide; Monoamine Oxidase Inhibitors; Morpholines; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Single-Blind Method; Sparteine	1993

Article

Year

Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

British journal of clinical pharmacology, 1993, Volume: 35, Issue:6

Topics: Adult; Aged; Benzamides; Cimetidine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Moclobemide; Monoamine Oxidase Inhibitors; Morpholines; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Single-Blind Method; Sparteine

1993

Other Studies

9 other study(ies) available for debrisoquin and cimetidine

Article	Year
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. International journal of clinical pharmacology, therapy, and toxicology, 1989, Volume: 27, Issue:12 Topics: Adult; Antipyrine; Biotransformation; Cimetidine; Debrisoquin; Half-Life; Humans; Hydroxylation; Isoquinolines; Male; Mixed Function Oxygenases; Phenobarbital; Phenotype; Rifampin	1989
The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. European journal of clinical pharmacology, 1989, Volume: 36, Issue:3 Topics: Adult; Cimetidine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Drug Interactions; Female; Humans; Hydroxylation; Isoquinolines; Male; Mixed Function Oxygenases; Phenotype; Time Factors	1989
Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs. Biochemical pharmacology, 1986, Aug-15, Volume: 35, Issue:16 Topics: Animals; Antipyrine; Cimetidine; Debrisoquin; Guanidines; Isoquinolines; Metoprolol; Microsomes, Liver; Ranitidine; Rats; Rats, Inbred Strains	1986
Inhibitor panel studies of human hepatic and placental cytochrome P-450-associated monooxygenase activities. Pharmacology & toxicology, 1988, Volume: 62, Issue:5 Topics: Aminoglutethimide; Animals; Benzoflavones; Cimetidine; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Enzyme Inhibitors; Female; Furans; Humans; Isoenzymes; Liver; Male; Metyrapone; Oxidoreductases; Placenta; Pregnancy; Rats; Rats, Inbred Strains	1988
Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clinical pharmacology and therapeutics, 1987, Volume: 42, Issue:3 Topics: Adult; Cimetidine; Debrisoquin; Desipramine; Half-Life; Humans; Hydroxylation; Isoquinolines; Kinetics; Metabolic Clearance Rate	1987